Cumberland Pharmaceuticals to Present at the UBS Global Life Sciences Conference in New York
NASHVILLE, Tenn., Sept. 13 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it will present a corporate overview at the UBS Global Life Sciences Conference at the Grand Hyatt New York on Monday, September 20, 2010, at 12:00 p.m. Eastern Time.
The presentation will be simultaneously webcast and can be accessed by visiting the Investor Relations section of Cumberland Pharmaceuticals' website at www.cumberlandpharma.com.
Shortly following the live webcast a replay will also be available on the Company's website.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote® for the treatment of acetaminophen poisoning, Caldolor®, the first injectable treatment for pain and fever approved in the United States, and Kristalose®, a prescription laxative. Cumberland is dedicated to providing innovative products which improve quality of care for patients. For more information on Cumberland Pharmaceuticals, please visit the Company website at www.cumberlandpharma.com.
Contact: |
|
Angela Novak |
|
Investor Relations |
|
(615) 255-0068 |
|
SOURCE Cumberland Pharmaceuticals Inc.
Share this article